Trial Outcomes & Findings for A Web-Based Multimedia Intervention for Head and Neck Cancer Patients (NCT NCT02442336)

NCT ID: NCT02442336

Last Updated: 2021-03-17

Results Overview

Psychological distress will be assessed using the Brief Symptom Inventory-18. The Brief Symptom Inventory-18 (BSI-18) is an 18-item scale widely used to measure psychological distress. The BSI-18 yields a total score (Global Severity Index), which is a measure of overall psychological distress. Raw scores are converted to t-scores (range 0-100) based on gender-specific normative data from cancer patient populations. A t-score of 50 is equal to the mean of the population. Higher scores represent greater levels of distress. The BSI-18 provides a clinical case-rule classifying respondents who have a t-score score ≥ 63 on the GSI as having clinically significant symptoms. Other studies have used a lower cutoff, with a GSI t-score ≥ 57 recommended as a cutoff for clinically significant symptoms in a study of cancer patients.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

80 participants

Primary outcome timeframe

Up to 6 weeks

Results posted on

2021-03-17

Participant Flow

Participant milestones

Participant milestones
Measure
My Journey AHead
Several internet modules will be developed to address mouth and swallowing concerns, oral care, healthy eating, speech problems, coping with cancer, pain management, and physical therapy. My Journey AHead: The intervention program will contain information and interactive activities around swallowing concerns, proper oral care, healthy eating and nutrition, speech issues, stress and coping with cancer, and pain management.
Overall Study
STARTED
80
Overall Study
Developmental Phase
6
Overall Study
Evaluation Phase
74
Overall Study
Provided Access to Intervention
55
Overall Study
COMPLETED
44
Overall Study
NOT COMPLETED
36

Reasons for withdrawal

Reasons for withdrawal
Measure
My Journey AHead
Several internet modules will be developed to address mouth and swallowing concerns, oral care, healthy eating, speech problems, coping with cancer, pain management, and physical therapy. My Journey AHead: The intervention program will contain information and interactive activities around swallowing concerns, proper oral care, healthy eating and nutrition, speech issues, stress and coping with cancer, and pain management.
Overall Study
6 patients assisted with the intervention development only.
6
Overall Study
Of the 74 who consented, 19 did not complete baseline assessment and were withdrawn from the study.
19
Overall Study
Lost to Follow-up
11

Baseline Characteristics

A Web-Based Multimedia Intervention for Head and Neck Cancer Patients

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
My Journey AHead
n=55 Participants
Participants were provided access to a web-base intervention that included several modules on oral care, stress and coping, nutrition, and pain management.
Age, Continuous
61.1 Years
STANDARD_DEVIATION 9.76 • n=5 Participants
Sex: Female, Male
Female
14 Participants
n=5 Participants
Sex: Female, Male
Male
41 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
0 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
6 Participants
n=5 Participants
Race (NIH/OMB)
White
49 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
Region of Enrollment
United States
55 participants
n=5 Participants
Brief Symptom Inventory-18
67.04 units on a scale
STANDARD_DEVIATION 4.123 • n=5 Participants
Cancer Behavior Inventory (CBI-B)
92.25 units on a scale
STANDARD_DEVIATION 12.70 • n=5 Participants

PRIMARY outcome

Timeframe: Up to 6 weeks

Psychological distress will be assessed using the Brief Symptom Inventory-18. The Brief Symptom Inventory-18 (BSI-18) is an 18-item scale widely used to measure psychological distress. The BSI-18 yields a total score (Global Severity Index), which is a measure of overall psychological distress. Raw scores are converted to t-scores (range 0-100) based on gender-specific normative data from cancer patient populations. A t-score of 50 is equal to the mean of the population. Higher scores represent greater levels of distress. The BSI-18 provides a clinical case-rule classifying respondents who have a t-score score ≥ 63 on the GSI as having clinically significant symptoms. Other studies have used a lower cutoff, with a GSI t-score ≥ 57 recommended as a cutoff for clinically significant symptoms in a study of cancer patients.

Outcome measures

Outcome measures
Measure
Web-Based Intervention
n=44 Participants
Participants were provided access to a web-base intervention that included several modules on oral care, stress and coping, nutrition, and pain management.
Patient Distress
66.16 units on a scale
Standard Deviation 4.77

Adverse Events

My Journey AHead

Serious events: 0 serious events
Other events: 50 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
My Journey AHead
n=55 participants at risk
Several internet modules will be developed to address mouth and swallowing concerns, oral care, healthy eating, speech problems, coping with cancer, pain management, and physical therapy. My Journey AHead: The intervention program will contain information and interactive activities around swallowing concerns, proper oral care, healthy eating and nutrition, speech issues, stress and coping with cancer, and pain management.
Psychiatric disorders
Elevated distress
90.9%
50/55 • Number of events 50 • A 3- to 6-week period during which participants were on-study (i.e. consented, completed baseline assessment, provided access to the intervention, and completed program evaluation).
Adverse events due to clinical treatment or medical management of the patient's disease were not specifically collected in this behavioral study, unless the patient reported it to the study team. We did not obtain IRB approval to conduct a medical chart review for incidence of treatment-related adverse events.

Additional Information

Carolyn Fang

Fox Chase Cancer Center

Phone: 215-728-4062

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place